• IBA Notice of Full Year 2023 Results and Conference Call

    ソース: Nasdaq GlobeNewswire / 26 2 2024 00:00:00   America/Chicago

    FY23 results meeting to take place as a hybrid event on
    Thursday, 21 March 2024 at 3pm CET

    Louvain-la-Neuve, Belgium, 26 February 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2023 on Thursday, 21 March 2024 at 7am CET.

    Conference Call Information

    IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, to present the half year results, followed by a Q&A session.

    The conference call will be held on Thursday, 21 March 2024 at 3pm CET / 2pm GMT / 10am ET / 7am PT as a Teams webinar and can be accessed online on this link.

    If you would like to join by phone only, please dial (Phone conference ID 204 708 166#):

    Belgium:                     +32 2 890 97 20
    UK:                             +44 20 3321 5200
    NL:                              +31 20 708 6901
    LU:                              +352 27 87 00 02
    US:                             +1 347-991-7591
    FR:                              +33 1 70 99 53 51

    The presentation will be available on IBA’s investor relations website and on https://www.iba-worldwide.com/full-year-results-2023-press-release-and-conference-call shortly before the call.

    To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

    For participants who do not have the Teams application installed, please follow the process described in this link to access the conference.

    ENDS

    About IBA

    IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

    IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

    More information can be found at: www.iba-worldwide.com

    CONTACTS

    Soumya Chandramouli
    Chief Financial Officer
    +32 10 475 890
    Investorrelations@iba-group.com

    Olivier Lechien
    Corporate Communication Director
    +32 10 475 890
    communication@iba-group.com

    ICR Consilium
    Amber Fennell, Matthew Neal, Lucy Featherstone
    +44 (0) 20 3709 5700
    IBA@consilium-comms.com

    Attachment


シェアする